BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention

Neurology

Volumn 88, Issue 22, 2017, Pages 2098-2106

  Boots, Elizabeth A ^a,b   Schultz, Stephanie A ^a,b   Clark, Lindsay R ^a,b,c   Racine, Annie M ^b   Darst, Burcu F ^c   Koscik, Rebecca L ^c   Carlsson, Cynthia M ^a,b,c   Gallagher, Catherine L ^a,b,c   Hogan, Kirk J ^c   Bendlin, Barbara B ^a,b,c   Asthana, Sanjay ^a,b,c   Sager, Mark A ^b,c   Hermann, Bruce P ^b,c   Christian, Bradley T ^b   Dubal, Dena B ^d   Engelman, Corinne D ^c   Johnson, Sterling C ^a,b,c   Okonkwo, Ozioma C ^a,b,c  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Department of Population Health Sciences ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; PITTSBURGH COMPOUND B; VALINE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HOMOZYGOTE; HUMAN; LEARNING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; SHORT TERM MEMORY; STROOP TEST; TIME; TRAIL MAKING TEST; WORKING MEMORY; BRAIN; COGNITION DISORDERS; DIAGNOSTIC IMAGING; DISEASE COURSE; EPISODIC MEMORY; EXECUTIVE FUNCTION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; REGISTER; WISCONSIN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; DISEASE PROGRESSION; EXECUTIVE FUNCTION; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; MEMORY, EPISODIC; MIDDLE AGED; POLYMORPHISM, GENETIC; REGISTRIES; WISCONSIN;

EID: 85020077006     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003980     Document Type: Article

References (40)

1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
2. Pietrzak RH, Lim YY, Ames D, et al. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol Aging 2015;36: 1231-1238.
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-923.
4. Okonkwo OC, Schultz SA, Oh JM, et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 2014;83:1753-1760.
5. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA 2011;108:3017-3022.
6. Boots EA, Schultz SA, Almeida RP, et al. Occupational complexity and cognitive reserve in a middle-aged cohort at risk for Alzheimer's disease. Arch Clin Neuropsychol 2015;30:634-642.
7. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012;11:1006-1012.
8. Song JH, Yu JT, Tan L. Brain-derived neurotrophic factor in Alzheimer's disease: risk, mechanisms, and therapy. Mol Neurobiol 2015;52:1477-1493.
9. Webster MJ, Herman MM, Kleinman JE, Shannon Weickert C. BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expr Patterns 2006;6:941-951.
10. Diniz BS, Teixeira AL. Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromolecular Med 2011;13:217-222.
11. Nagahara AH, Mateling M, Kovacs I, et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci 2013;33:15596-15602.
12. Rohe M, Synowitz M, Glass R, Paul SM, Nykjaer A, Willnow TE. Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. J Neurosci 2009;29:15472-15478.
13. Kimura N, Takahashi M, Tashiro T, Terao K. Amyloid beta up-regulates brain-derived neurotrophic factor production from astrocytes: rescue from amyloid betarelated neuritic degeneration. J Neurosci Res 2006;84: 782-789.
14. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-269.
15. Honea RA, Cruchaga C, Perea RD, et al. Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer's disease neurodegeneration. PLoS One 2013;8:e76001.
16. Lim YY, Villemagne VL, Laws SM, et al. BDNF Val66Met, Abeta amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging 2013;34:2457-2464.
17. Miyajima F, Ollier W, Mayes A, et al. Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav 2008;7: 411-417.
18. Kennedy KM, Reese ED, Horn MM, et al. BDNF val66-met polymorphism affects aging of multiple types of memory. Brain Res 2015;1612:104-117.
19. Hariri AR, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003;23:6690-6694.
20. Weinstein G, Beiser AS, Choi SH, et al. Serum brainderived neurotrophic factor and the risk for dementia: The Framingham Heart Study. JAMA Neurol 2014;71: 55-61.
21. Buchman AS, Yu L, Boyle PA, Schneider JA, De Jager PL, Bennett DA. Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology 2016;86:735-741.
22. Feher A, Juhasz A, Rimanoczy A, Kalman J, Janka Z. Association between BDNF Val66Met polymorphismand Alzheimer disease, dementia with Lewy bodies, and Pick disease. Alzheimer Dis Assoc Disord 2009; 23:224-228.
23. Nagata T, Shinagawa S, Nukariya K, Yamada H, Nakayama K. Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease. Dement Geriatr Cogn Disord 2012;33:266-272.
24. Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 2005;18:245-249.
25. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575.
26. Koscik RL, La Rue A, Jonaitis EM, et al. Emergence of mild cognitive impairment in late middle-aged adults in the Wisconsin Registry for Alzheimer's Prevention. Dement Geriatr Cogn Disord 2014;38:16-30.
27. Schultz SA, Larson J, Oh J, et al. Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease. Brain Imaging Behav 2015;9:729-736.
28. Floberg JM, Mistretta CA, Weichert JP, Hall LT, Holden JE, Christian BT. Improved kinetic analysis of dynamic PET data with optimized HYPR-LR. Med Phys 2012;39: 3319-3331.
29. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 2005;25:1528-1547.
30. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
31. Schultz SA, Boots EA, Almeida RP, et al. Cardiorespiratory fitness attenuates the influence of amyloid on cognition. J Int Neuropsychol Soc 2015;21:841-850.
32. Curran-Everett D. Multiple comparisons: philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol 2000;279:R1-R8.
33. Singer JD, Willett JB. Applied Longitudinal Data Analysis. New York: Oxford University Press; 2003.
34. Racine AM, Clark LR, Berman SE, et al. Associations between performance on an Abbreviated CogState battery, other measures of cognitive function, and biomarkers in people at risk for Alzheimer's disease. J Alzheimers Dis 2016;54:1395-1408.
35. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015;138:2020-2033.
36. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNFbased synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 2013;14: 401-416.
37. Lim YY, Villemagne VL, Laws SM, et al. Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: A preliminary study. PLoS One 2014;9:e86498.
38. Adamczuk K, De Weer AS, Nelissen N, et al. Polymorphism of brain derived neurotrophic factor influences beta amyloid load in cognitively intact apolipoprotein E epsilon4 carriers. Neuroimage Clin 2013;2:512-520.
39. Zhang L, Fang Y, Lian Y, et al. Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer's disease induced by abeta1-42. PLoS One 2015;10:e0122415.
40. Lee J, Seroogy KB, Mattson MP. Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J Neurochem 2002;80:539-547.